Pharmacogenomics of IFN-β in multiple sclerosis: Towards a personalized medicine approach

Pharmacogenomics

Volumn 10, Issue 1, 2009, Pages 97-108

  Vosslamber, Saskia ^a   van Baarsen, Lisa G M ^a   Verweij, Cornelis L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Disease subtypes; DNA microarray; Heterogeneity; Molecular profiling; Multiple sclerosis; Personalized medicine; Pharmacogenomics

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA 2 MICROGLOBULIN; BETA INTERFERON; BETA1A INTERFERON; CD56 ANTIGEN; EPITHELIAL STROMAL INTERACTION PROTEIN 1; GENE PRODUCT; GLYCOPROTEIN P 15095; INTERCELLULAR ADHESION MOLECULE 3; INTERFERON; INTERFERON ALPHA INDUCIBLE PROTEIN 27; INTERFERON BETA SERINE; INTERLEUKIN 1 RECEPTOR; JANUS KINASE; MYXOVIRUS RESISTANCE PROTEIN; NEOPTERIN; PLACEBO; STAT PROTEIN; TRIPARTITE MOTIF CONTAINING 69; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; RECOMBINANT INTERFERON;

ANTIINFLAMMATORY ACTIVITY; CELL CYCLE REGULATION; CLINICAL TRIAL; CYTOKINE RELEASE; DEMYELINATION; DOWN REGULATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NERVOUS SYSTEM DEVELOPMENT; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENOMICS; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; DRUG EFFECT; GENE EXPRESSION; GENETICS; PHARMACOGENETICS; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INTERFERON TYPE I, RECOMBINANT; MULTIPLE SCLEROSIS; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 62649151993     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.1.97     Document Type: Review

References (62)

1. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C: Multiple sclerosis. Immunol. Rev. 204, 208-231 (2005).
2. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group: Interferon-β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45(7), 1277-1285 (1995).
3. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E: Defining interferon-β response status in multiple sclerosis patients. Ann. Neurol. 56(4), 548-555 (2004).
4. Sibley WA, Bamford CR, Clark K: Clinical viral infections and multiple sclerosis. Lancet 1(8441), 1313-1315 (1985).
5. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G: The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon-β-1b. Neurology 52(6), 1277-1279 (1999).
6. Reske D, Walser A, Haupt WF, Petereit HF: Long-term persisting interferon-β-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol. Scand. 109(1), 66-70 (2004).
7. Vartanian TK, Zamvil SS, Fox E, Sorensen PS: Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 63(11 Suppl. 5), S42-S49 (2004).
8. Sadler AJ, Williams BR: Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8(7), 559-568 (2008).
9. Muller U, Steinhoff U, Reis LF et al.: Functional role of type I and type II interferons in antiviral defense. Science 264(5167), 1918-1921 (1994).
10. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998).
11. Coccia EM: IFN regulation and functions in myeloid dendritic cells. Cytokine Growth factor Rev. 19(1), 21-32 (2008).
12. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N: IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19, 623-655 (2001).
13. Litinskiy MB, Nardelli B, Hilbert DM et at.: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3(9), 822-829 (2002).
14. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19(2), 225-234 (2003).
15. Chawla-Sarkar M, Lindner DJ, Liu YF et al.: Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3), 237-249 (2003).
16. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu. Rev. Biochem 67, 227-264 (1998).
17. Takaoka A, Yanai H: Interferon signaling network in innate defence. Cell. Microbiol. 8(6), 907-922 (2006).
18. Ghislain JJ, Fish EN: Application of genomic DNA affinity chromatography identifies multiple interferon-α-regulated Stat2 complexes. J. Biol. Chem. 271(21), 12408-12413 (1996).
19. Li X, Leung S, Qureshi S, Darnell JE Jr, Stark GR: Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-α. J. Biol. Chem. 271(10), 5790-5794 (1996).
20. Ghislain JJ, Wong T, Nguyen M, Fish EN: The interferon-inducible Stat2:Stat1 heterodimer preferentially binds in vitro to a consensus element found in the promoters of a subset of interferon-stimulated genes. J. Interferon Cytokine Res. 21(6), 379-388 (2001).
21. Takaoka A, Taniguchi T: New aspects of IFN-α/β signaling in immunity, oncogenesis and bone metabolism. Cancer Sci. 94(5), 405-411 (2003).
22. Brierley MM, Fish EN: Functional relevance of the conserved DNA-binding domain of STAT2. J. Biol. Chem. 280(13), 13029-13036 (2005).
23. Der SD, Zhou A, Williams BR, Silverman RH: Identification of genes differentially regulated by interferon-α, β, or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95(26), 15623-15628 (1998).
24. Dupont SA, Goelz S, Goyal J, Green M: Mechanisms for regulation of cellular responsiveness to human IFN-β1a. J. Interferon Cytokine Res. 22(4), 491-501 (2002).
25. Song MM, Shuai K: The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J. Biol. Chem. 273(52), 35056-35062 (1998).
26. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y et al.: Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell Biol. 22(16), 5662-5668 (2002).
27. Liu B, Mink S, Wong KA et al.: PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat. Immunol. 5(9), 891-898 (2004).
28. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT: Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J. Neuroimmunol. 129(1-2), 205-215 (2002).
29. Hertzog PJ, Wright A, Harris G, Linnane AW, Mackay IR: Intermittent interferonemia and interferon responses in multiple sclerosis. Clin. Immunol. Immunopathol. 58(1), 18-32 (1991).
30. Wandinger KP, Wessel K, Neustock P, Siekhaus A, Kirchner H: Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis. J. Neurol. Sci. 149(1), 87-93 (1997).
31. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ et al.: A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun. 7(6), 522-531 (2006).
32. Yamaguchi KD, Ruderman DL, Croze E et al.: IFN-β-regulated genes show abnormal expression in therapy-naive relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported pfotein-protein interactions. J. Neuroimmunol. 195(1-2), 116-120 (2008).
33. Witt PL, Storer BE, Bryan GT et al.: Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β. J. Immunother. Emphasis Tumor Immunol. 13(3), 191-200 (1993).
34. Chiang J, Gloff CA, Yoshizawa CN, Williams GJ: Pharmacokinetics of recombinant human interfefon-β set in healthy volunteers and its effect on serum neopterin. Pharm. Res. 10(4), 567-572 (1993).
35. Alam. J, Goelz S, Rioux P et al.: Comparative pharmacokinctics and pharmacodynamics of two recombinant human interferon-β-1a (IFN-β-1 a) products administered intramuscularly in healthy male and female volunteers. Pharm. Res. 14(4), 546-549 (1997).
36. Munafo A, Trinchard-Lugan I I, Nguyen TX, Buraglio, M: Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon-β-1a after intramuscular and subcutaneous administration. Eur. J. Neurol. 5(2), 187-193 (1998).
37. Rothuizen LE, Buclin T, Spertini F et al.: Influence of interferon-β-1a dose frequency on PBMC cytokine secretion and biological effect markers. J. Neuroimmunol. 99(1), 131-141 (1999).
38. Iglesias AH, Camelo S, Hwang D, Villanueva R, Stephanopoulos G, Dangond F: Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 150(1-2), 163-177 (2004).
39. Achiron A, Gurevich M, Magalashvili D, Kisbner I, Dolev M, Mandel M: Understanding autoimmune mechanisms in multiple sclerosis using gene expression microarrays: treatment effect and cytokine-related pathways. Clin. Dev. Immunol. 11(3-4), 299-305 (2004).
40. Sturzebecher S, Maibauer R, Heurter A, Beckmann K, Aufdembrinke B: Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J. Interferon Cytokine Res. 19(11), 1257-1264 (1999).
41. Bjerrum OW, Nissen MH, Borregaard N: Neutrophil β-2 microglobulin: an inflammatory mediator. Scand. J. Immunol. 32(3), 233-242 (1990).
42. Hilpert J, Beekman JM, Schwenke S et al.: Biological response genes after single dose administration of interferon-β-1b to healthy male volunteers. J. Neuroimmunol. 199 (1-2), 115-125 (2008).
43. Kantor AB, Deng J, Waubant E et al.: Identification of short-term pharmacodynamic effects of interferon-β-1a in multiple sclerosis subjects with broad-based phenotypic profiling. J. Neuroimmunol. 188(1-2), 103-116 (2007).
44. Penkowa M, Hidalgo J: Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis. J. Neurosci. Res. 72(5), 574-586 (2003).
45. Williams GJ, Witt PL: Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J. Interferon Cytokine Res. 18(11), 967-975 (1998).
46. Wandinger KP, Sturzebecher CS, Bielekova B et al.: Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 50(3), 349-357 (2001).
47. Satoh J, Nanri Y, Tabunoki H, Yamamura T: Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFN-β-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFN-β-related adverse effects in multiple sclerosis. BMC Neurol. 6, 18 (2006).
48. Weinstock-Guttman B, Badgett D, Patrick K et al.: Genomic effects of IFN-β in multiple sclerosis patients. J. Immunol. 171(5), 2694-2702 (2003).
49. Sturzebecher S, Wandinger KP, Rosenwald A et al.: Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain 126(Pt 6), 1419-1429 (2003).
50. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD: Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy. J. Neurol. Sci. 258(1-2), 52-59 (2007).
51. Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM: Novel interferon-β-induced gene expression in peripheral blood cells. J. Leukoc. Biol. 82(5), 1353-1360 (2007).
52. Annibali V, di Giovanni S, Cannoni S et al.: Gene expression profiles reveal homeostatic dynamics during interferon-β therapy in multiple sclerosis. Autoimmunity 40(1), 16-22 (2007).
53. Fernald GH, Knott S, Pachner A et al.: Genome-wide network analysis reveals the global properties of IFN-β immediate transcriptional effects in humans. J. Immunol. 178(8), 5076-5085 (2007).
54. Redef AT, Velichko S, Yamaguchi KD et al.: IFN-β1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J. Interferon Cytokine Res. 28(5), 317-331 (2008).
55. Hartrich L, Weinstock-Guttman B, Hall D et al.: Dynamics of immune cell trafficking in interferon-β treated multiple sclerosis patients. J. Neuroimmunol. 139(1-2), 84-92 (2003).
56. Rudick RA, Lee JC, Simon J, Fisher E: Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann. Neurol. 60(2), 236-242 (2006).
57. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ: Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125(Pt 8), 1676-1695 (2002).
58. van Baarsen LG, Vosslamber S, Tijssen M et al.: Pharmacogenomics of interferon-β therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 3(4), E1927 (2008).
59. Stone LA, Frank JA, Albert PS et al.: The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 37(5), 611-619 (1995).
60. Baranzini SE, Mousavi P, Rio J et al.: Transcription-based prediction of response to IFN-β using supervised computational methods. PLoS Biol. 3(1), E2 (2005).
61. Lehtonen A, Matikainen S, Jułkunen I: Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J. Immunol. 159(2), 794-803 (1997).
62. Gresser I: Biologic effects of interferons. J. Invest. Dermatol. 95(Suppl. 6), S66-S71 (1990).